Literature DB >> 10913121

Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor.

M T Overgaard1, J Haaning, H B Boldt, I M Olsen, L S Laursen, M Christiansen, G J Gleich, L Sottrup-Jensen, C A Conover, C Oxvig.   

Abstract

Pregnancy-associated plasma protein-A (PAPP-A), originally known from human pregnancy serum, has recently been demonstrated to be a metzincin superfamily metalloproteinase involved in normal and pathological insulin-like growth factor (IGF) physiology. PAPP-A specifically cleaves IGF-binding protein (IGFBP)-4, one of six antagonists of IGF action, which results in release of IGF bound to IGFBP-4. IGFBP-4 is the only known PAPP-A substrate. Its cleavage by PAPP-A uniquely depends on the presence of IGF. We here report mammalian expression and purification of recombinant 1547-residue PAPP-A (rPAPP-A). The recombinant protein is secreted as a homodimer of about 400 kDa composed of two 200-kDa disulfide-bound subunits. Antigenically and functionally, rPAPP-A behaves like the native protein. In human pregnancy, PAPP-A is known to circulate as a 500-kDa disulfide-bound 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP. A comparison between rPAPP-A and pregnancy serum PAPP-A/proMBP complex surprisingly reveals a difference greater than 100-fold in proteolytic activity, showing that proMBP functions as a proteinase inhibitor in vivo. We find that polyclonal antibodies against PAPP-A abrogate all detectable IGFBP-4 proteolytic activity in pregnancy serum, pointing at PAPP-A as the dominating, if not the only, IGFBP-4 proteinase present in the circulation. We further show that pregnancy serum and plasma contain traces (<1%) of uncomplexed PAPP-A with a much higher specific activity than the PAPP-A/proMBP complex. The measurable activity of the PAPP-A/proMBP complex probably results from the presence of a minor subpopulation of partly inhibited PAPP-A that exists in a 2:1 complex with proMBP. Inhibition of PAPP-A by proMBP represents a novel inhibitory mechanism with the enzyme irreversibly bound to its inhibitor by disulfide bonds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913121     DOI: 10.1074/jbc.M001384200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.

Authors:  Makoto Nakasato; Hitoshi Kohsaka; Tetsuya Mizutani; Gen Watanabe; Kazuyoshi Taya; Kentaro Nagaoka
Journal:  Endocrine       Date:  2012-08-17       Impact factor: 3.633

2.  Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development.

Authors:  Cheryl A Conover; Megan A Mason; Laurie K Bale; Sean C Harrington; Mette Nyegaard; Claus Oxvig; Michael T Overgaard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-14       Impact factor: 4.733

Review 3.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Trimerization domain of the collagen tail of acetylcholinesterase.

Authors:  Suzanne Bon; Annick Ayon; Jacqueline Leroy; Jean Massoulié
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 5.  First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.

Authors:  S Shiefa; M Amargandhi; J Bhupendra; S Moulali; T Kristine
Journal:  Indian J Clin Biochem       Date:  2012-10-12

6.  Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.

Authors:  Sabine Heitzeneder; Elena Sotillo; Jack F Shern; Sivasish Sindiri; Peng Xu; Robert Jones; Michael Pollak; Pernille R Noer; Julie Lorette; Ladan Fazli; Anya Alag; Paul Meltzer; Ching Lau; Cheryl A Conover; Claus Oxvig; Poul H Sorensen; John M Maris; Javed Khan; Crystal L Mackall
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

7.  Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis.

Authors:  Lisbeth S Laursen; Michael T Overgaard; Claus G Nielsen; Henning B Boldt; Kathrin H Hopmann; Cheryl A Conover; Lars Sottrup-Jensen; Linda C Giudice; Claus Oxvig
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

Review 8.  Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2.

Authors:  Virginia D Winn; Matthew Gormley; Agnes C Paquet; Kasper Kjaer-Sorensen; Anita Kramer; Kristen K Rumer; Ronit Haimov-Kochman; Ru-Fang Yeh; Michael T Overgaard; Ajit Varki; Claus Oxvig; Susan J Fisher
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

Review 9.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

10.  Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.

Authors:  A J Ryan; S Napoletano; P A Fitzpatrick; C A Currid; N C O'Sullivan; J H Harmey
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.